KLCM
IBB icon

KG&L Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

KG&L Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,100
Closed -$38K – 107
2018
Q4 		$38K Buy
+4,100
New +$435K 0.04% 89

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

KG&L Capital Management's IBB Position: Q2 2024 in Review

KG&L Capital Management sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 1,751 shares — an estimated $240K sold.

KG&L Capital Management first reported a position in IBB in Q4 2018 and held it in 13 quarters. The position peaked at $619K in Q2 2021. 895 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

  • KG&L Capital Management reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
  • KG&L Capital Management sold 1,751 iShares Biotechnology ETF shares in Q2 2024, an estimated $240K.
  • KG&L Capital Management first reported a position in iShares Biotechnology ETF in Q4 2018 and held it in 13 quarters.
  • KG&L Capital Management's iShares Biotechnology ETF position peaked at $619K in Q2 2021.
  • 895 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on KG&L Capital Management's 13F filing for Q2 2024, filed 23 Jul 2024.